Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
MYTX-011 incorporates Mythic’s FateControl™ technology, which holds the potential to dramatically improve ADC efficacy, thereby expanding the number of NSCLC